RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $42 to $37.
July 31, 2024 | 2:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on Pacira BioSciences but lowers the price target from $42 to $37.
The Outperform rating suggests continued confidence in Pacira BioSciences' performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100